title: A review of the effectiveness of vaccine potency control testing.
abstract: The use of potency control testing is a valuable tool for testing the actual relative strength of manufactured assembly lots of vaccine. Biological-based manufacturing methods are inherently variable and potency testing is a tool to ensure lot-to-lot consistency of commercial vaccines. A strong historical link to clinical efficacy has been established where correlation to efficacy and adequate test validation have been achieved. The link to immunogenicity and efficacy has traditionally been strongest with attenuated vaccines and toxoids. Control potency test failure does predict that a serial or batch of vaccine would most likely provide insufficient immunogenicity in typical field applications. Because of the complexity of pathogenic processes and associated immune responses, potency tests may not always directly predict the effectiveness of a vaccine. Thus, vaccines that pass control potency testing may not always provide adequate efficacy. This is particularly true of adjuvanted, inactivated vaccines. In the development of vaccine formulations and control tests for vaccines, the nature of the desired protective immune responses to the targeted pathogen (when known) should be considered. These considerations could provide better alternatives in the assays chosen as correlates of immunity and may more accurately predict efficacy and assure batch-to-batch consistency. Also, the effects of the dose and duration of antigen exposure as well as the nature of antigen presentation and generation of extrinsic cytokines could be characterised and correlated to vaccine potency as additional indicators of vaccine efficacy.
authors.affiliation: Biologicals Development, Veterinary Medicine Research and Development, Pfizer Animal Health, Pfizer, Inc., Eastern Point Road, 8118D-2001, Groton, CT 06340, USA. d_scott_mcvey@groton.pfizer.com
authors.forename: David Scott
authors.initials: DS
authors.lastname: McVey
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Galvin
authors.forename: Steven C
authors.initials: SC
authors.lastname: Olson
mesh_terms: D000276:Adjuvants, Immunologic; D000917:Antibody Formation / Q000276:immunology; D000941:Antigens / Q000276:immunology; D019411:Clinical Laboratory Techniques; D006801:Humans; D007109:Immunity / Q000276:immunology; D011315:Preventive Medicine; D015203:Reproducibility of Results; D014121:Toxoids / Q000592:standards; D016896:Treatment Outcome; D014612:Vaccines / Q000276:immunology / Q000592:standards*; D014613:Vaccines, Attenuated / Q000592:standards; D014774:Virulence / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000941:Antigens; D014121:Toxoids; D014612:Vaccines; D014613:Vaccines, Attenuated